1-3 of 3
Margaret J. Uprichard, PharmD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphoctyic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen.

Khuda D. Khan, MD, PhD, Susan O’Brien, MD, Kanti R. Rai, MD, Jennifer R. Brown, MD, PhD, Perry Cook, MD, Anne Marie Maddox, MD, Alison M. Duarte, MPH, Eric J. Haltom, Margaret J. Uprichard, PharmD
Journal: Blood
Blood (2005) 106 (11): 2125.
https://doi.org/10.1182/blood.V106.11.2125.2125
Published: 2005
Journal Articles

Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma with Primary Resistance to or Progression Following Rituximab.

Ayad Al-Katib, MD, David D. Hurd, MD, Robert Raju, MD, Joe Stephenson, MD, Francis Giles, MD, Eric Haltom, Margaret J. Uprichard, PharmD
Journal: Blood
Blood (2004) 104 (11): 1403.
https://doi.org/10.1182/blood.V104.11.1403.1403
Published: 2004
Journal Articles

Phase 1 Rising Multiple-Dose Study of Talabostat (PT-100) in Healthy Subjects.

Margaret J. Uprichard, PharmD, Barry Jones, PhD
Journal: Blood
Blood (2004) 104 (11): 4215.
https://doi.org/10.1182/blood.V104.11.4215.4215
Published: 2004